Form 8-K - Current report:
SEC Accession No. 0001723128-26-000008
Filing Date
2026-02-27
Accepted
2026-02-27 06:16:22
Documents
14
Period of Report
2026-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20260227.htm   iXBRL 8-K 28606
2 EX-99.1 amrx-q42025ex991.htm EX-99.1 508794
6 GRAPHIC imagea.jpg GRAPHIC 3187
  Complete submission text file 0001723128-26-000008.txt   695813

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20260227.xsd EX-101.SCH 1876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20260227_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20260227_pre.xml EX-101.PRE 12599
17 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20260227_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 26692376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)